EVEKEO

Post-LOE

amphetamine sulfate

R-Pharm US

ANDAORALTABLET

Approved

Aug 2012

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

EVEKEO (amphetamine sulfate) by R-Pharm US is clinical pharmacology amphetamines are non-catecholamine, sympathomimetic amines with cns stimulant activity. Approved for attention deficit hyperactivity disorder (adhd) in patients 13 years, older [see clinical studies ()], older and 1 more indications. First approved in 2012.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Amphetamines are non-catecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures, and weak bronchodilator, and respiratory stimulant action. Amphetamine, as the racemic form, differs from…

Worked on EVEKEO at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

EVEKEO

Mechanism of Action

Indications (3)